ROYALTIES AND EXPENSES. 6.1 [***].
6.2 All payments to PHS, required under this Agreement, shall be in [***] and payment options are listed in Appendix A.
(a) Institution shall submit to MS annual statements of itemized Expenses as defined in Paragraph 2.3 and shall deduct the Expenses as provided for in Paragraph 2.2, except where PITS has identified discrepancies in billing by Institution, in which case, deduction of the contested item(s), as a part of Expenses as provided for in Paragraph 2.2, from Net Revenues shall be delayed pending resolution thereof.
6.3 In no event shall PHS be obligated to bear any costs for Expenses under this Agreement.
6.4 Each party shall be solely responsible for calculating and distributing to its respective Inventor(s) of the Patent Rights any share of Net Revenues in accordance with its respective patent policy, royalty policy, or Federal law during the term of this Agreement.
ROYALTIES AND EXPENSES. The Institution shall distribute Net Revenues to the IC concurrently with distributions it makes under the Institution's patent policy, but in any case not later than April 1 for the preceding calendar year, on the following basis: (a) ______ percent (X%) of the Net Revenues as a royalty to the Institution and (b) ______ percent (X%) of the Net Revenues as a royalty to the IC. All payments to the IC, required under this Agreement, shall be in U.S. dollars and payment options are listed in Appendix A. Any loss of exchange, value, taxes, or other expenses incurred in the transfer or conversion to U.S. dollars shall be paid entirely by the Institution; and Additional royalties may be assessed by the IC on any payment that is more than ninety (90) days overdue at the rate of one percent (1%) per month. This one percent (1%) per month rate may be applied retroactively from the original due date until the date of receipt by the IC of the overdue payment and additional royalties. The payment of any additional royalties shall not prevent the IC from exercising any other rights it may have as a consequence of the lateness of any payment. The Institution shall submit to the IC annual statements of itemized Expenses as defined in Paragraph 2.4 and shall deduct the Expenses as provided for in Paragraph 2.3, except where IC has identified discrepancies in billing by the Institution, in which case, deduction of the contested item(s), as a part of the Expenses as provided for in Paragraph 2.4, shall be delayed pending resolution thereof. In no event shall the IC be obligated to bear any costs for Expenses under this Agreement. Each party shall be solely responsible for calculating and distributing to its respective Inventor(s) of the Patent Rights any share of Net Revenues in accordance with its respective patent policy, royalty policy, or Federal law during the term of this Agreement.
ROYALTIES AND EXPENSES. 6.1 The IC shall distribute Net Revenues to the Institution concurrently with distributions it makes under the IC's patent policy on the following basis: (a) percent (X%) of the Net Revenues as a royalty to the Institution and (b) percent (X%) of the Net Revenues as a royalty to the IC. All payments to the Institution, required under this Agreement, shall be in U.S. dollars and shall be made by check or bank draft drawn on a United States bank and made payable to . All payments shall be sent to the following address: .
6.2 The IC shall submit to the Institution annual statements of itemized Expenses, as defined in Paragraph 2.4, and shall deduct the Expenses as provided for in Paragraph 2.3, except where the Institution has identified discrepancies in billing by the IC, in which case, deduction of the contested item(s), as a part of Expenses as provided for in Paragraph 2.4, shall be delayed pending resolution thereof.
6.3 In no event shall the Institution be obligated to bear any costs for the Expenses under this Agreement.
6.4 Each party shall be solely responsible for calculating and distributing to its respective Inventor(s) of the Patent Rights any share of the Net Revenues in accordance with its respective patent policy, royalty policy, or Federal law during the term of this Agreement.
ROYALTIES AND EXPENSES. 6.1 The Institution shall distribute Net Revenues to the IC concurrently with distributions it makes under the Institution's patent policy, but in any case not later than April 1 for the preceding calendar year, on the following basis: (a) percent (X%) of the Net Revenues as a royalty to the Institution and
ROYALTIES AND EXPENSES. Except as set forth on Schedule 4.17 or to the extent funds are currently held in suspense for which the Purchase Price is adjusted pursuant to Section 2.4(b) or which are transferred to Purchaser’s on or after to Closing under any Contract, to the Knowledge of Seller as of the Execution Date, (a) all material rentals, royalties, excess royalty, overriding royalty interests and other payments due under or with respect to the Oil and Gas Properties have been properly and timely paid (or held in suspense) and (b) all material expenses payable under the terms of the Contracts have been properly and timely paid except for such expenses as are being currently paid prior to delinquency in the ordinary course of business.
ROYALTIES AND EXPENSES. 6.1 The NIH shall distribute Net Revenues to the Institution concurrently with distributions it makes under the NIH's patent policy on the following basis: (a) percent (X%) of the Net Revenues as a royalty to the Institution and (b) percent (X%) of the Net Revenues as a royalty to the NIH. All payments to the Institution, required under this Agreement, shall be in U.S. dollars and shall be made by check or bank draft drawn on a United States bank and made payable to . All payments shall be sent to the following address: .
6.2 The NIH shall submit to the Institution annual statements of itemized Expenses, as defined in Paragraph 2.5, and shall deduct the Expenses as provided for in Paragraph 2.4, except where the Institution has identified discrepancies in billing by the NIH, in which case, deduction of the contested item(s), as a part of Expenses as provided for in Paragraph 2.4, shall be delayed pending resolution thereof.
6.3 In no event shall the Institution be obligated to bear any costs for the Expenses under this Agreement.
6.4 Each party shall be solely responsible for calculating and distributing to its respective Inventor(s) of the Patent Rights any share of the Net Revenues in accordance with its respective patent policy, royalty policy, or Federal law during the term of this Agreement.
ROYALTIES AND EXPENSES. 8.1 Lead Institution will distribute to Partner Institution’s Net Revenues accrued during the most recently completed quarter interval not later than forty-five (45) days of receipt of such funds by Lead Institution. Any part of Net Revenues received by Lead Institution as equity will be held in escrow. Partner Institution’s equity share will be held in the name of “The Xxxx Xxxxxx Specialist Hospital and Research Centre”.
8.2 Lead Institution will submit to Partner Institution’s annual statements of itemized Expenses, and Net Revenues due Partner Institution under Paragraph 8.1 of this Agreement, except where Partner Institution have identified discrepancies in billing by Lead Institution, in which case deduction of the contested item from Net Revenues will be delayed pending resolution thereof under Paragraph 11.2 of this Agreement.
8.3 A. The Parties will share in Net Revenues as follows:
(i) where Lead Institution has either covered at its sole expense without reimbursement out of Net Revenue, or secured from Licensee full reimbursement of all reasonable and actual out-of-pocket costs incurred by Lead Institution in the preparation, filing, prosecution, and licensing if Inventions: 60% -- Lead Institution 40% -- Partner Institution
(ii) where Lead Institution has neither covered at its own expense nor secured from Licensee full reimbursement of all reasonable and actual out-of -pocket costs incurred by Lead Institution in the preparation, filing, prosecution, and licensing of Inventions: 50% -- Lead Institution 50% -- Partner Institution
ROYALTIES AND EXPENSES. Except as set forth on Schedule 5.18, to the Knowledge of Seller, as of the Execution Date, (a) all material Royalties payable by the Company Group have been properly and timely paid (or which constitute Suspense Funds) and (a) all material expenses payable by the Company Group under the terms of the Contracts have been properly and timely paid except, in each case, for such Royalties and expenses (x) as are being currently paid prior to delinquency in the ordinary course of business or (y) the amount or validity of which is being contested in good faith by appropriate proceedings and for which appropriate reserves have been established.
ROYALTIES AND EXPENSES. 6.1 [***].
6.2 All payments to the NIH, required under this Agreement, shall be in [***] and payment options arc listed in Appendix A.
6.3 The Institution shall submit to the NIH annual statements of itemized Expenses as defined in Paragraph 2.5 and shall deduct the Expenses as provided for in Paragraph 2.4, except where NIH has identified discrepancies in billing by the Institution, in which case, deduction of the contested item(s), as a part of the Expenses as provided for in Paragraph 2.4, from Net Revenues shall be delayed pending resolution thereof.
6.4 In no event shall the NIH be obligated to bear any costs for Expenses under this Agreement.
6.5 Each party shall be solely responsible for calculating and distributing to its respective Inventor(s) of the Patent Rights any share of Net Revenues in accordance with its respective patent policy, royalty policy, or Federal law during the term of this Agreement.
ROYALTIES AND EXPENSES. (a) The first [***] of Net Revenues derived from Licensee Agreements and/or sales transactions of one or more NEOMAGIC Patents will accrue entirely to NEOMAGIC. Thereafter, for all Net Revenues in excess of the first [***], except as provided in section 2.2(b) above, NEOMAGIC shall pay to CONSORTIUM royalty payments (the “Royalty Payments”) calculated as follows:
(i) [***] of Net Revenues derived from Licensee Agreements;
(ii) [***] of all Net Revenues associated with sales transactions of one or more NEOMAGIC Patents, and
(iii) an additional one-time bonus of [***] if CONSORTIUM exceeds performance targets established by agreement with NEOMAGIC.
(b) If NEOMAGIC is compensated by a Licensee in other than financial terms under (i) or (ii) above, then the parties will negotiate in good faith to determine a comparable amount of compensation to CONSORTIUM in lieu of the Royalty Payments. [***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission.
(c) If NEOMAGIC licenses or sells all or part of the Patent Rights to a third party and CONSORTIUM is not involved, and has not been involved, at any time, in the introduction of, or the negotiation or transaction with, the third party, then the “Royalty Payments” that NEOMAGIC shall pay to CONSORTIUM, as specified above in Section 4.1(a), (i) and (ii), shall be reduced [***] to [***] in Section 4.1(a)(i) and from [***] to [***] in Section 4.1(a)(ii), and NEOMAGIC shall pay such reduced payments to CONSORTIUM.
4.2 The Royalty Payments due hereunder to CONSORTIUM shall be paid in full without deduction of taxes or other fees which may be imposed by any government and shall be paid by NEOMAGIC to CONSORTIUM within a thirty (30) day period following the end of each calendar quarter in which NEOMAGIC receives payment of the Net Revenues.
4.3 Royalty Payments shall be paid to CONSORTIUM in United States dollars. If any currency conversion shall be required in connection with the payment of royalties hereunder, such conversion shall be made by using the mid point of the exchange rate specified by The Wall Street Journal on the last business day of the calendar quarterly reporting period to which such Royalty Payments relate.
4.4 CONSORTIUM shall be responsible for paying all of its out-of-pocket expenses incurred in connection with its efforts to facilitate the obtaining of Net Reve...
